[Explanation] On February 28, at Wuhan Institute of Biological Products, Duan Kai, director of Sinopharm Wuhan Institute of Biological Products, and Yuan Zhiming, president of Wuhan Branch of Chinese Academy of Sciences, publicly displayed the inactivated vaccine for the new crown jointly developed by the two units.
This is not only the second new crown vaccine approved for conditional marketing by China Biotech, but also the third inactivated vaccine approved for marketing conditionally in China.
On the same day, the first batch of "Wuhan-made" new crown inactivated vaccines that were approved to be listed on the market started off the line.
[Concurrent] Duan Kai, Director of Sinopharm Wuhan Institute of Biological Products:
This inactivated vaccine of Wuhan Institute of Biology has good clinical safety. After vaccination, its protection rate is its antibody titer. The neutralizing antibody titer is very high, and the positive conversion rate can reach 99.06%. The protection of diagnosed moderately severe patients can reach 100%, and the comprehensive protection can reach 72.51%. All the data meet the technical standards of us, the World Health Organization, and the corresponding technology formulated by our State Food and Drug Administration. index.
[Explanation] Wuhan Institute of Biological Products has built a new crown inactivated vaccine biosafety workshop, which has been put into large-scale production after inspection and certification by relevant national departments.
[Concurrent] Duan Kai, Director of Sinopharm Wuhan Institute of Biological Products:
According to our current construction scale, our annual production capacity can reach about 100 million doses (times).
[Explanation] On April 12, 2020, Wuhan Institute of Biological Products of China Biosciences obtained the world's first clinical approval for a new coronavirus inactivated vaccine and simultaneously carried out I/II clinical trials. The statistical results show that the safety of the vaccine is good after vaccination; different After the procedure and different doses of vaccination, all the vaccinated persons in the vaccine group produced high-titer antibodies.
On June 23, the UAE Minister of Health issued a clinical trial approval document to China Biotech, marking the official launch of the world's first international clinical trial (Phase III) of the new crown inactivated vaccine.
On June 30, the first batch of the vaccine was put into emergency use, and emergency vaccinations were successively carried out for specific populations in China.
[Explanation] On the same day, Sinopharm's China Bio-Central Industrial Base was inaugurated simultaneously.
The base is centered on the Wuhan Institute of Biological Products project, focusing on the production of vaccines, blood preparations and therapeutic biological drugs, and will become a modern biological drug industrialization base.
The relevant person in charge of Wuhan said that the industrial base will play an important role in promoting the development of a trillion-level health industry cluster in Wuhan, and promoting Wuhan's post-epidemic recovery and rebirth.
Reporter Zou Hao reports from Wuhan, Hubei
Editor in charge: 【Luo Pan】